Evotec AG, a biotechnology company, engages in the discovery and development of small molecule drugs through its own discovery programmes and research collaborations. The company operates in two divisions, Pharmaceuticals and Services. The Pharmaceuticals division focuses on developing central nervous system (CNS) drugs. Its product pipeline includes EVT 201, a GABAA receptor modulator for the treatment of insomnia, which is under phase II clinical trials; EVT 101, a subtype-selective NMDA receptor antagonist for the treatment of Alzheimer’s disease and neuropathic pain, which is under phase II clinical trials; EVT 302, a selective and reversible inhibitor of MAO-B for smoking cessation, which is under phase I clinical trials; and EVT 102, a preclinical development product for pre-emptive analgesia and post-operative pain in a hospital setting. The Services division provides integrated contract research support in drug discovery and development to worldwide customers. This division offers a range of integrated solutions, including early stage assay development and screening through to medicinal chemistry and drug manufacturing. Evotec has collaboration agreements with Apeiron Biologics to discover pain therapeutics; Boehringer Ingelheim for a drug discovery programme; Roche to discover and develop compounds for CNS diseases and other indications; and DAC for HSP90 cancer project, as well as has a strategic partnership with CHDI for the treatment of Huntington disease. The company, formerly known as EVOTEC BioSystems GmbH, was founded in 1993. Evotec is based in Hamburg, Germany.